Research Sample bioBank
Can’t find what you’re looking for? Contact us.
Or, need help ordering? 805.528.4341
Get Weekly Research Sample Updates in your Inbox:
Hepatitis C (HCV) Genotype 3 Clinical Research Samples
Discovery Life Sciences provides the highest quality Hepatitis C (HCV) Genotype 3 Clinical Research Samples and Residual Diagnostic Specimens from the Life Science Industry’s only convenient online, open access Biobank.
- All Hepatitis C (HCV) Genotype 3 Sample Orders are Packaged for Delivery within 24 Hours.
- All Specimens Ethically Obtained, De-Identified and provided with Highly Annotated Demographic and Clinical Data.
- Select from an HHS/OHRP Compliant Biorepository following ISBER/BBRB Guidelines.
- Packaged in Compliance with all UN Regulations (6.2) and U.S. DOT Hazmat regulations.
Advanced Data View:
Showing 28 of 28 total samples
Buy | Product ID | Sample | Origin | Matrix | Vial (ml) | Quantity | Price | Age | Gender | Ethnicity | Storage Temp | Sample Date | Test 1 | Test Data 1 | Sample Detail 1 | Test 2 | Test Data 2 | Sample Detail 2 | Test 3 | Test Data 3 | Product Details | Price | Buy | Additional Information 1 | Additional Data 1 | Additional Detail 1 | Additional Information 2 | Additional Data 2 | Additional Detail 2 | Additional Information 3 | Additional Data 3 | Additional Information 4 | Additional Data 4 | Additional Detail 4 | Additional Information 5 | Additional Data 5 | Additional Detail 5 | Additional Information 6 | Additional Data 6 | Additional Detail 6 | Additional Information 7 | Additional Data 7 | Additional Detail 7 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DLS12-6267 | Hepatitis C (HCV) Genotype 3 | Australia | Serum | 1.00 | 10.00 | $95.00 | 47 Y | F | White | <-70°C | 21-Aug-13 | Viral Load | U/A | Innogenetics Versant HCV | 3a | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | No symptoms | |||||||||||||||||||
| DLS12-6271 | Hepatitis C (HCV) Genotype 3 | Italy | Serum | 1.00 | 10.00 | $95.00 | 56 Y | M | White | <-70°C | 05-Apr-13 | Real-Time PCR | 111,089 U/mL | Siemens TruGene HCV | 3a | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Transfusion | Symptoms | Decreased appetite; Fatigue | Additional Testing | ALT: 45; AST: 57; ALP: 247; LDH: 401; Bilirubin: 0.83; Serum Creatinine: 1.21 mg/dL; Hepatocellular Carcinoma | Hepatitis Serology | anti HCV+ (Abbott) | |||||||||||||||
| DLS12-6275 | Hepatitis C (HCV) Genotype 3 | Italy | Serum | 1.00 | 3.00 | $95.00 | 56 Y | F | White | <-70°C | 13-Feb-13 | Roche cobas | 440,000 IU/mL | Innogenetics Versant HCV | 3a | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | IV Drug Abuse | Symptoms | Fatigue; Depression | |||||||||||||||||||
| DLS12-7485 | Hepatitis C (HCV) Genotype 3 | Spain | Citrated Plasma | 1.00 | 8.00 | $40.00 | 49 Y | M | U/A | <-70°C | 18-Apr-12 | Roche cobas | 404,479 IU/mL | HCV Ct Value - 21 | Innogenetics INNO-LIPA | 3a | $40.00 | Symptoms | Asymptomatic | Hepatitis Serology | Anti-HCV S/CO - 6.28 (Abbott PRISM) | ||||||||||||||||||||||
| DLS13-02054 | Hepatitis C (HCV) Genotype 3 | Australia | K2 EDTA Plasma | 1.00 | 1.00 | $95.00 | 39 Y | F | White | <-70°C | 19-Jun-13 | Roche cobas | 241,000 IU/mL | Innogenetics Versant HCV | 3a | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | IV Drug Abuse | Symptoms | Depression | |||||||||||||||||||
| DLS13-02065 | Hepatitis C (HCV) Genotype 3 | Australia | K2 EDTA Plasma | 1.00 | 1.50 | $95.00 | 41 Y | M | White | <-70°C | 17-Apr-13 | Roche cobas | 10,200 IU/mL | Innogenetics Versant HCV | 3a | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | IV Drug Abuse | Symptoms | Fatigue | |||||||||||||||||||
| DLS13-02066 | Hepatitis C (HCV) Genotype 3 | Australia | K2 EDTA Plasma | 1.00 | 1.50 | $95.00 | 48 Y | M | White | <-70°C | 08-May-13 | Roche cobas | 32,900 IU/mL | Innogenetics Versant HCV | 3a | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | IV Drug Abuse | Symptoms | Fatigue | |||||||||||||||||||
| DLS13-03325 | Hepatitis C (HCV) Genotype 3 | Spain | Citrated Plasma | 1.00 | 12.00 | $40.00 | 45 Y | F | U/A | < -70C | 29-Aug-12 | Roche cobas | 40,890 IU/mL | HCV Ct Value - 23 | Innogenetics INNO-LIPA | 3a | $40.00 | Abbott PRISM | 7.11 S/Co | Anti-HCV | Is Subject on Anti-Viral Therapy / Treatment | No | Symptoms | Asymptomatic | |||||||||||||||||||
| DLS13-03327 | Hepatitis C (HCV) Genotype 3 | Spain | Citrated Plasma | 1.00 | 10.00 | $40.00 | 57 Y | F | U/A | < -70C | 28-Feb-12 | Roche cobas | 30,850 IU/mL | HCV Ct Value - 24 | Innogenetics INNO-LIPA | 3a | $40.00 | Abbott PRISM | 7.75 S/Co | Anti-HCV | Is Subject on Anti-Viral Therapy / Treatment | No | Symptoms | Asymptomatic | |||||||||||||||||||
| DLS13-03329 | Hepatitis C (HCV) Genotype 3 | Spain | Citrated Plasma | 1.00 | 7.00 | $40.00 | 49 Y | M | U/A | < -70C | 05-Jan-08 | Roche cobas | 5,889 IU/mL | HCV Ct Value - 25 | Innogenetics INNO-LIPA | 3a | $40.00 | Abbott PRISM | 10.54 S/Co | Anti-HCV | Is Subject on Anti-Viral Therapy / Treatment | No | Symptoms | Asymptomatic | Other Testing Results | Immunoblot C100(4+) C33(4+) C22(4+) NS5(4+) | |||||||||||||||||
| DLS13-03336 | Hepatitis C (HCV) Genotype 3 | Spain | Citrated Plasma | 1.00 | 5.00 | $40.00 | 42 Y | M | U/A | < -70C | 24-Nov-12 | Roche cobas | 816,427 IU/mL | HCV Ct Value - 22 | Innogenetics INNO-LIPA | 3a | $40.00 | Abbott PRISM | 5.71 S/Co | Anti-HCV | Is Subject on Anti-Viral Therapy / Treatment | No | Symptoms | Asymptomatic | |||||||||||||||||||
| DLS13-05042 | Hepatitis C (HCV) Genotype 3 | Vietnam | K2 EDTA Plasma | 1.00 | 15.00 | $95.00 | 35 Y | M | Asian | < -70C | 09-Sep-13 | Roche cobas | 1,120,000 copies/mL | Genotype by RT PCR | 1 | 3 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | Yes | Interferon | Acquired Infection Category | IV Drug Abuse | Symptoms | No symptoms | ||||||||||||||||||
| DLS13-09608 | Hepatitis C (HCV) Genotype 3 | Vietnam | Serum | 1.00 | 7.00 | $95.00 | 46 Y | M | Asian | < -70C | 19-Dec-13 | Roche cobas | 59,400 IU/mL | Real-Time PCR | 3 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Transfusion | Symptoms | Decreased appetite; Fatigue; Abdominal pain | Additional Testing | ALT: 66 U/L; AST: 157 U/L; Bilirubin: 24.3 umol/L; Serum Creatinine: 81 umol/L | Hepatitis Serology | HBsAg- (ECLIA Cobas 6000) | |||||||||||||||
| DLS13-16672 | Hepatitis C (HCV) Genotype 3 | Italy | Serum | 1.00 | 5.00 | $95.00 | 43 Y | M | White | < -70C | 12-Jun-13 | Real-Time PCR | 1,178,956 U/mL | Siemens TruGene HCV | 3a | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Transfusion; Piercing; Tattoo | Symptoms | Fatigue; Jaundice | Additional Testing | ALT: 57; AST: 89; ALP: 42; LDH: 559; Bilirubin: 1.21; Serum Creatinine: 0.7 mg/dL; Cirrhosis | Hepatitis Serology | anti HCV+ | 2006 | ||||||||||||||
| DLS14-05376 | Hepatitis C (HCV) Genotype 3 | Vietnam | Serum | 1.00 | 6.00 | $95.00 | 40 Y | M | Asian | < -70C | 22-May-14 | Roche cobas | 24,800 copies/mL | Genotype by RT PCR | 1 | 3 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | Yes | Tenofovir 300 mg; Lamivudine 150 mg; Aluvia 200/50 mg | Acquired Infection Category | Sexual Transmission; IV Drug Abuse | Symptoms | No symptoms | Additional Testing | ALT: 81; AST: 55; Serum Creatinine: 134 umol/L | Hepatitis Serology | HBsAg-; Anti HCV+ (Elisa) | Co-Infections | HIV+ | 2004 | |||||||||||
| DLS14-05406 | Hepatitis C (HCV) Genotype 3 | Vietnam | Serum | 1.00 | 8.00 | $95.00 | 27 Y | M | Asian | < -70C | 18-Aug-14 | Roche cobas | 10,000,000 copies/mL | 10-Aug-14 | Genotype by RT PCR | 1 | 3 | 14-Oct-14 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Decrease appetite; Fatigue; Jaundice | Additional Testing | ALT: 343; AST: 368; Bilirubin: 20.7 umol/L; Serum Creatinine: 0.9 mg/dL | 13-Aug-14 | Hepatitis Serology Result | |||||||||||||
| DLS14-07997 | Hepatitis C (HCV) Genotype 3 | Vietnam | Serum | 1.00 | 11.00 | $95.00 | 38 Y | M | Asian | <-70C | 12-Aug-15 | Roche cobas | 13,800,000 IU/mL | 7-Aug-15 | Real-Time PCR | 3 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Sexual transmission | Symptoms | No symptoms | ||||||||||||||||||
| DLS14-08050 | Hepatitis C (HCV) Genotype 3 | Vietnam | Serum | 1.00 | 4.00 | $95.00 | 38 Y | M | Asian | <-70C | 14-May-15 | Roche cobas | 3,320,000 copies/mL | 10-Sep-10 | Real-Time PCR | 1 | 3 | 21-May-15 | $95.00 | 3-series HepB Vaccine | Yes | Is Subject on Anti-Viral Therapy / Treatment | Yes | Zidovudine 300 mg, Lamivudine 150 mg, Efavirnez 100 mg | Acquired Infection Category | IV Drug Abuse | Symptoms | No symptoms | ||||||||||||||||
| DLS16-67477 | Hepatitis C (HCV) Genotype 3 | Vietnam | Serum | 1.00 | 6.00 | $95.00 | 45 Y | M | Asian | <-70C | 17-Apr-17 | Roche Cobas | 1,600 IU/mL | 17-Apr-17 | Genotype by RT PCR | 3 | 19-Apr-17 | $95.00 | 3-Series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | None | Acquired Infection Category | Unknown | Symptoms | Fatigue; Jaundice | Additional Testing | ALT: 62 U/L,AST: 41 U/L, Bilirubin: 14 umol/L, Serum Creatinine: 54 umol/L, Chronic HCV | 13-Apr-2017 | Hepatitis Serology | HCV Ab + | Co-Infections | None | |||||||||
| DLS16-67616 | Hepatitis C (HCV) Genotype 3 | Vietnam | Serum | 1.00 | 4.00 | $95.00 | 32 Y | M | Asian | <-70C | 03-Mar-17 | Roche Cobas | 4,830,000 IU/mL | 1-Mar-17 | Genotype by RT PCR | 3 | 8-Mar-17 | $95.00 | 3-Series HepB Vaccine | Yes | Is Subject on Anti-Viral Therapy / Treatment | Yes | Tenofovir; Lamivudine; Efavirenz | Acquired Infection Category | IV Drug Abuse | Symptoms | Decreased appetite; Fatigue; Abdominal pain | Additional Testing | ALT: 39 U/L, AST: 25 U/L , Bilirubin: 29 umol/L, Serum Creatinine: 78 umol/L, HCV 2012 | 1-Mar-2017 | Hepatitis Serology | None | Co-Infections | HIV+ | 28-May-12 | ||||||||
| DLS0025526 | Hepatitis C (HCV) Genotype 3 | South Africa | Serum | 1.00 | 9.00 | $95.00 | 58 Y | M | White | <-70C | 23-Sep-15 | Roche cobas | 5,460,000 IU/mL | Viral Load | Siemens Versant Lipa | 3a | Genotype | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Piercing | Tattoo | Symptoms | Fatigue; Decreased Appetite | Additional Testing | ALT: 37; AST: 59; ALP: 204; Bilirubin: 26 umol/L; Serum Creatinine: 79 umol/L | 23-Sep-15 | Hepatitis Serology | U/A | Co-Infections | Chronic HCV | ||||||||||
| DLS16-72205 | Hepatitis C (HCV) Genotype 3 | Italy | Serum | 1.00 | 8.00 | $95.00 | 52 Y | F | White | <-70C | 28-Sep-17 | Roche cobas | 4,880,000 IU/mL | 29-Jun-17 | Siemens TruGene HCV 5NC | 3a | 29-Jun-17 | HCV Date of Diagnosis | 29-Jun-17 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | U/A | Symptoms | Fatigue | Additional Testing | ALT: 50 U/L | AST: 50 U/L | Bilirubin: 1.7 mg/dL | Serum Creatinine: 0.9 mg/dL | | Liver Cirrhosis from HCV | 9-Oct-17 | Diasorin Liaison Serology Results | HBsAg-, HBsAb+, HBcAb+, | 29-Jun-17 | Co-Infections | None | |||||||
| DLS16-72208 | Hepatitis C (HCV) Genotype 3 | Italy | Serum | 1.00 | 8.00 | $95.00 | 58 Y | F | White | <-70C | 14-Nov-17 | Roche cobas | 656,000 IU/mL | 8-Sep-17 | Siemens TruGene HCV 5NC | 3a | 8-Sep-17 | HCV Date of Diagnosis | 8-Sep-17 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | U/A | Symptoms | No symptoms | Additional Testing | ALT: 32 U/L | AST: 64 U/L | ALP: 103 U/L | Bilirubin: 0.3 mg/dL | Serum Creatinine: 0.7 mg/dL | Chronic Hepatitis C | 22-Mar-17 | Diasorin Liaison Serology Results | HBsAg-, HBsAb+, HBcAb+, | 8-Sep-17 | Co-Infections | None | |||||||
| DLS16-72211 | Hepatitis C (HCV) Genotype 3 | Italy | Serum | 1.00 | 9.00 | $95.00 | 38 Y | M | White | <-70C | 26-Oct-17 | Roche cobas | 261,000 IU/mL | 26-Oct-17 | Siemens TruGene HCV 5NC | 3a | 26-Oct-17 | HCV Date of Diagnosis | 26-Oct-17 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | U/A | Symptoms | Depression | Additional Testing | ALT: 74 U/L | AST: 49 U/L | LDH: 173 U/L | Bilirubin: 0.5 mg/dL | Serum Creatinine: 0.5 mg/dL | Chronic Hepatitis C | 23-Oct-17 | Diasorin Liaison Serology Results | HBsAg-, HBsAb+, HBcAb+, HCVAb+, | 23-Oct-17 | Co-Infections | None | |||||||
| DLS0025524 | Hepatitis C (HCV) Genotype 3 | Italy | Serum | 1.00 | 8.00 | $95.00 | 56 Y | M | White | <-70C | 12-Jan-18 | Roche cobas | 362,115 IU/mL | HCV Viral Load | Genotype | 3a | 6-Nov-17 | 3-series HepB Vaccine | No | $95.00 | Acquired Infection Category | U/A | Is Subject on Anti-Viral Therapy / Treatment | No | Current Symptoms | Fatigue | Additional Testing | Bilirubin: 2.3 mg/dL | Creatinine: 1.0 mg/dL | Chronic Hepatitis C | 6-Nov-17 | Hepatitis Serology | HBsAg- | HBsAb- | HBcAb- | (CMIA) | 6-Nov-17 | Co-Infections | None | |||||||||
| DLS0083216 | Hepatitis C (HCV) Genotype 3 | Italy | Serum | 1.00 | 12.00 | $95.00 | 39 Y | M | White | <-70C | 29-Jun-18 | Roche cobas | 66,000 IU/mL | HCV Viral Load | Genotype | 3 | 29-Jun-18 | 3-series HepB Vaccine | No | $95.00 | Acquired Infection Category | U/A | Is Subject on Anti-Viral Therapy / Treatment | No | Current Symptoms | No symptoms | Additional Testing | Bilirubin: 0.78 mg/dL | Creatinine: 0.7 mg/dL | Chronic Hepatitis C | 10-Jul-18 | Hepatitis Serology | HBsAg- | HBsAb+ | HBcAb+ | (CMIA) | 31-May-18 | Co-Infections | None | |||||||||
| KHBR-1735 | Hepatitis C (HCV) Genotype 3 | USA | Serum | 2.25 | 1.00 | $95.00 | 47 Y | M | White | <-70C | 16-Apr-18 | Roche COBAS | Taqman | 230,947 | HCV RNA PCR | $95.00 | Freeze Date | 05.15.18 | HEP C+: Genotype 3 | |||||||||||||||||||||||||
| DLS0116317 | Hepatitis C (HCV) Genotype 3 | USA | Serum | 1.75 | 1.00 | $95.00 | Y | F | U/A | <-70C | 02-Oct-17 | RT-PCR | 135000 IU/mL | HCV | HCV log: 5.1 | $95.00 | Genotype | 3 |
Keep in mind that all the samples comprised in the Research Sample Biobank represent only a small number of the clinical research specimens available through our Discovery Partners™ clinical research programs. If you can’t find the specific sample type, specimen or biofluids you are looking for please make sure to call our client services group at 805.528.4341 - and ask how we can help support your project from resources available at active clinical sites.
Please read carefully before purchasing:
Clinical specimens for research use only.
Transmissible Infectious Risk! May be HIV, HBV and HCV REACTIVE or of unknown infectious agent test status. Materials provided are derived from human blood, tissue and other bio-fluids. Handle all samples as if capable of transmitting infectious agents. Practice good laboratory technique and dispose of in properly marked medical waste.
If you need help searching for a LARGER SAMPLE SET with specific data elements, please contact our Client Services group who can format Excel spreadsheets for a comprehensive review of all available samples: USA (805) 528-4341
These products are supplied without warranty for suitability for specific applications or analytical determinations.
Specimens and data will be may be used for general biomarker research, assay and instrument validation purposes only. All Research products identified as “Diagnostic Remnant Samples” are human biological materials leftover from routine laboratory analysis and are de-identified (coded) to protect subject confidentiality. Under OHRP definition 45 CFR 46.102(f) these coded specimens are not considered subjects for Human research requiring informed consent. Specimens cannot be used for whole genomic sequencing of genetic material. Research products designated as “Clinical Research Samples” by “type” are obtained from IRB approved research study protocols with informed consent obtained from each subject enrolled. Specimens cannot be used for whole genomic sequencing of genetic material.